ISRAELI HEADs INT’l DIABETES STUDY Prof. Itamar Raz, director of the diabetes unit at the Hadassah University Medical Center in Jerusalem’s Ein Kerem, has begun to co-chair a large international research trial on a Type 2 diabetes medication. Called SAVOR (Saxagliptin in Assessment of Vascular Outcomes Recorded in Patients with Diabetes Melliuts), the trial is aimed at assessing the effects of saxagliptin, Onglyza, a novel DPP4 inhibitor that enhances response to incretin (a hormone that works to increase insulin activity) on cardiovascular events in Type 2 diabetes patients. Diabetics are at higher risk of developing heart disease.Raz will co-chair the study in collaboration with Dr. Eugene Braunwald of the TIMI Group in Boston, a world leader in conducting clinical trials that assess the care of patients with coronary artery diseases. The SAVOR study is sponsored by the Bristol-Myers Squibb/AstraZeneca Diabetes Collaboration, which is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of Type 2 diabetes, which is affecting growing numbers of people around the world.SAVOR will be conducted over five years in several countries worldwide e– including Israel – with targeted enrollment of 12,000 patients with Type 2 diabetes. Onglyza has been approved in 40 countries, including the US, and by the European Union and was recently submitted for registration in Israel. “This study is aimed at assessing that a new medication from the family of incretin medications has any impact on decreasing the risk of cardiovascular events and its related mortality in patients with Type 2 diabetes,” said Raz said. “It is an honor to collaborate with Dr. Braunwald and the TIMI Group and I look forward to working with them.” Two principal investigators – an endocrinologist and a cardiologist – were selected to lead the project in each participating country. In addition to co-chairing the international effort, Raz was asked to lead the Israeli research team in conjunction with Prof. Basil Lewis of Haifa’s Carmel Medical Center. An international scientific committee will supervise the execution of the project and convene once every few months to analyze the data and provide recommendations on the direction of the research. Raz and Prof. Eran Leitersdorf, dean of Hebrew University Medical Faculty are members of this committee.
EAT SLOWLYFast food may make those exposed who eat it regularly impatient and less willing to save money, according to researchers Chen-Bo Zhong and Sanford DeVoe of the University of Toronto. According to a UPI report on an article in the journal Psychological Science, merely flashing a fast-food logo for milliseconds on a computer screen caused study participants – compared to controls – to increase reading speed although there was no advantage to finishing sooner. “The problem is that the goal of saving time gets activated uponexposure to fast food regardless of whether time is a relevant factorin the context,”Zhong said in a statement. “For example, walking fasteris time efficient when one is trying to make a meeting, but it's a signof impatience when one is going for a stroll in the park.”In another experiment, participants asked to recall having fast-foodsubsequently preferred time-saving products such as two-in-one shampoo(conditioner plus shampoo) to regular products. A third experimentlinked fast-food exposure to spending preferences – they preferred asmaller immediate payment rather than a larger later payment.“The ironic thing is that by constantly reminding us of timeefficiency, these technologies can lead us to feel much moreimpatience, DeVoe said.